Gao-Xiang Wang

Clinical management strategies for cytokine release syndrome and their impact on CAR T-cell efficacy in lymphoma.

Chimeric antigen receptor T-cell (CAR-T) therapy has significantly advanced the treatment of relapsed/refractory (R/R) lymphoma. However, its broader clinical application is often limited by cytokine release syndrome (CRS), a major immune-mediated complication. Because the in vivo expansion of CAR-T cells drives both t...